Skip to main content

Table 1 Baseline characteristics of treatment group and placebo

From: Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy

  Treatment (n=17) Placebo (n=17)
Gender (males: females) 13: 4 14: 3
Age (years) (SD) 74.5 (4.2) 73.5 (4.0)
Smoking (n/total) 1/17 1/17
Hypertension (n/total) 12/17 13/17
BMI (kg/m2) (SD) 25.6 (3.4) 26.8 (8.3)
Chronic AF (n/total) 11/17 9/17
Duration of AF (years)(SD) 13.5 (15.0) 14.0 (19.3)
  1. Data as mean (SD). AF, atrial fibrillation; BMI, body mass index;n, number of patients; SD, standard deviation.